PL2917217T3 - Podstawione tricykliczne benzimidazole jako inhibitory kinazy - Google Patents
Podstawione tricykliczne benzimidazole jako inhibitory kinazyInfo
- Publication number
- PL2917217T3 PL2917217T3 PL13786679T PL13786679T PL2917217T3 PL 2917217 T3 PL2917217 T3 PL 2917217T3 PL 13786679 T PL13786679 T PL 13786679T PL 13786679 T PL13786679 T PL 13786679T PL 2917217 T3 PL2917217 T3 PL 2917217T3
- Authority
- PL
- Poland
- Prior art keywords
- kinase inhibitors
- substituted tricyclic
- tricyclic benzimidazoles
- benzimidazoles
- substituted
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220157.0A GB201220157D0 (en) | 2012-11-08 | 2012-11-08 | Substitute tricyclic benzimidazoles as kinase inhibitors |
| PCT/EP2013/073311 WO2014072435A1 (en) | 2012-11-08 | 2013-11-07 | Substituted tricyclic benzimidazoles as kinase inhibitors |
| EP13786679.4A EP2917217B1 (en) | 2012-11-08 | 2013-11-07 | Substituted tricyclic benzimidazoles as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2917217T3 true PL2917217T3 (pl) | 2017-10-31 |
Family
ID=47470315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13786679T PL2917217T3 (pl) | 2012-11-08 | 2013-11-07 | Podstawione tricykliczne benzimidazole jako inhibitory kinazy |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9745299B2 (pl) |
| EP (1) | EP2917217B1 (pl) |
| JP (1) | JP6101812B2 (pl) |
| KR (1) | KR101812390B1 (pl) |
| CN (1) | CN104903321B (pl) |
| AU (1) | AU2013343550B2 (pl) |
| BR (1) | BR112015010019B1 (pl) |
| CA (1) | CA2890643C (pl) |
| CY (1) | CY1119084T1 (pl) |
| DK (1) | DK2917217T3 (pl) |
| ES (1) | ES2628046T3 (pl) |
| GB (1) | GB201220157D0 (pl) |
| HR (1) | HRP20170802T1 (pl) |
| HU (1) | HUE033485T2 (pl) |
| IL (1) | IL238693A0 (pl) |
| LT (1) | LT2917217T (pl) |
| MX (1) | MX363609B (pl) |
| PL (1) | PL2917217T3 (pl) |
| PT (1) | PT2917217T (pl) |
| RS (1) | RS56056B1 (pl) |
| SI (1) | SI2917217T1 (pl) |
| SM (1) | SMT201700291T1 (pl) |
| WO (1) | WO2014072435A1 (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6521387B2 (ja) | 2014-04-18 | 2019-05-29 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| AU2016348659B2 (en) * | 2015-11-03 | 2022-07-28 | Apriligen, Inc. | Compounds for treatment of hypoproliferative disorders |
| CN114921468A (zh) | 2017-01-30 | 2022-08-19 | 国立大学法人京都大学 | 新型化合物以及调节性t细胞的制造方法 |
| EP3591040A4 (en) * | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS |
| AU2018249154A1 (en) * | 2017-04-03 | 2019-11-21 | Kyoto Pharmaceutical Industries, Ltd. | Novel cyclin-dependent kinase 8 and/or 19 inhibitor |
| WO2019068613A1 (en) | 2017-10-02 | 2019-04-11 | Boehringer Ingelheim International Gmbh | NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS |
| AU2019326633B2 (en) * | 2018-08-24 | 2022-09-08 | Adlai Nortye Biopharma Co., Ltd. | High activity sting protein agonist |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3877371A4 (en) | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| US20220056044A1 (en) * | 2018-12-14 | 2022-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof |
| BR112021017831A2 (pt) * | 2019-03-11 | 2021-11-30 | Collaborative Medicinal Dev Llc | Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose |
| AU2020357983B2 (en) * | 2019-10-03 | 2025-11-13 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| CN111349094B (zh) * | 2020-04-23 | 2021-02-02 | 杭州师范大学 | 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用 |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| JP7805009B2 (ja) | 2020-11-20 | 2026-01-23 | オリヅルセラピューティクス株式会社 | 成熟化剤 |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| TW202246489A (zh) | 2021-02-09 | 2022-12-01 | 日商千紙鶴治療公司 | 成熟化劑 |
| EP4313050A4 (en) * | 2021-03-25 | 2025-02-12 | University of South Carolina | CDK8/19 INHIBITORS FOR CYTOKINIC STORM TREATMENT |
| AU2022349176A1 (en) | 2021-09-27 | 2024-04-11 | Kyoto University | Method for producing t cell |
| WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| US20250018033A1 (en) | 2021-11-24 | 2025-01-16 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
| MX2024006370A (es) | 2021-11-24 | 2024-08-19 | Regcell Co Ltd | Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t. |
| CN119256076A (zh) | 2022-03-23 | 2025-01-03 | 国立大学法人京都大学 | 用于产生调节性t细胞的方法 |
| AU2023262842A1 (en) | 2022-04-25 | 2024-09-12 | Orizuru Therapeutics, Inc. | Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity |
| WO2023241627A1 (en) * | 2022-06-15 | 2023-12-21 | Insilico Medicine Ip Limited | Cdk8/19 dual inhibitors and methods of use thereof |
| WO2024014497A1 (ja) | 2022-07-14 | 2024-01-18 | オリヅルセラピューティクス株式会社 | 細胞移植用のフィブリンゲルシート |
| EP4600352A1 (en) | 2022-09-26 | 2025-08-13 | Kyoto University | T cell production method |
| EP4596684A1 (en) | 2022-09-26 | 2025-08-06 | Regcell Co., Ltd. | Induced regulatory t cells containing chimeric antigen receptor (car) |
| KR20250140618A (ko) | 2023-02-08 | 2025-09-25 | 레그셀 가부시키가이샤 | 천포창을 치료 또는 예방하기 위한 의약 조성물 |
| JPWO2024204553A1 (pl) | 2023-03-29 | 2024-10-03 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2899757B2 (ja) | 1989-06-26 | 1999-06-02 | 持田製薬株式会社 | ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体 |
| US5500423A (en) | 1994-09-09 | 1996-03-19 | Hoechst-Roussel Pharmaceuticals Inc. | 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines |
| EP1309594B1 (fr) * | 2000-08-08 | 2004-12-15 | Sanofi-Aventis | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| WO2003051879A1 (en) | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| AU2003240742A1 (en) * | 2002-06-07 | 2003-12-22 | Altana Pharma Ag | 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors |
| US20070032469A1 (en) * | 2005-08-05 | 2007-02-08 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| AR056556A1 (es) * | 2005-09-30 | 2007-10-10 | Astrazeneca Ab | Imidazo(1,2-a)piridina con actividad antiproliferacion celular |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| RU2013138835A (ru) * | 2011-02-09 | 2015-03-20 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
-
2012
- 2012-11-08 GB GBGB1220157.0A patent/GB201220157D0/en not_active Ceased
-
2013
- 2013-11-07 CA CA2890643A patent/CA2890643C/en active Active
- 2013-11-07 MX MX2015005772A patent/MX363609B/es unknown
- 2013-11-07 WO PCT/EP2013/073311 patent/WO2014072435A1/en not_active Ceased
- 2013-11-07 SI SI201330669T patent/SI2917217T1/sl unknown
- 2013-11-07 BR BR112015010019-8A patent/BR112015010019B1/pt active IP Right Grant
- 2013-11-07 ES ES13786679.4T patent/ES2628046T3/es active Active
- 2013-11-07 EP EP13786679.4A patent/EP2917217B1/en active Active
- 2013-11-07 LT LTEP13786679.4T patent/LT2917217T/lt unknown
- 2013-11-07 US US14/441,785 patent/US9745299B2/en active Active
- 2013-11-07 RS RS20170565A patent/RS56056B1/sr unknown
- 2013-11-07 KR KR1020157014733A patent/KR101812390B1/ko active Active
- 2013-11-07 AU AU2013343550A patent/AU2013343550B2/en active Active
- 2013-11-07 HR HRP20170802TT patent/HRP20170802T1/hr unknown
- 2013-11-07 PL PL13786679T patent/PL2917217T3/pl unknown
- 2013-11-07 DK DK13786679.4T patent/DK2917217T3/en active
- 2013-11-07 HU HUE13786679A patent/HUE033485T2/en unknown
- 2013-11-07 JP JP2015541140A patent/JP6101812B2/ja active Active
- 2013-11-07 SM SM20170291T patent/SMT201700291T1/it unknown
- 2013-11-07 PT PT137866794T patent/PT2917217T/pt unknown
- 2013-11-07 CN CN201380064124.XA patent/CN104903321B/zh active Active
-
2015
- 2015-05-07 IL IL238693A patent/IL238693A0/en active IP Right Grant
-
2017
- 2017-06-06 CY CY20171100592T patent/CY1119084T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2890643C (en) | 2018-05-22 |
| GB201220157D0 (en) | 2012-12-26 |
| JP2016503408A (ja) | 2016-02-04 |
| KR20150091074A (ko) | 2015-08-07 |
| MX2015005772A (es) | 2015-11-18 |
| LT2917217T (lt) | 2017-07-25 |
| MX363609B (es) | 2019-03-28 |
| EP2917217B1 (en) | 2017-03-08 |
| CY1119084T1 (el) | 2018-01-10 |
| SMT201700291T1 (it) | 2017-07-18 |
| EP2917217A1 (en) | 2015-09-16 |
| KR101812390B1 (ko) | 2017-12-26 |
| WO2014072435A1 (en) | 2014-05-15 |
| BR112015010019A2 (pt) | 2017-07-11 |
| DK2917217T3 (en) | 2017-06-19 |
| IL238693A0 (en) | 2015-06-30 |
| CN104903321B (zh) | 2017-10-24 |
| PT2917217T (pt) | 2017-06-07 |
| US9745299B2 (en) | 2017-08-29 |
| SI2917217T1 (sl) | 2017-08-31 |
| HRP20170802T1 (hr) | 2017-08-11 |
| JP6101812B2 (ja) | 2017-03-22 |
| BR112015010019A8 (pt) | 2019-09-17 |
| CN104903321A (zh) | 2015-09-09 |
| BR112015010019B1 (pt) | 2022-08-09 |
| AU2013343550B2 (en) | 2016-09-22 |
| AU2013343550A1 (en) | 2015-05-14 |
| ES2628046T3 (es) | 2017-08-01 |
| RS56056B1 (sr) | 2017-09-29 |
| HUE033485T2 (en) | 2017-12-28 |
| US20150274726A1 (en) | 2015-10-01 |
| CA2890643A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289834A (en) | Conversion of tricyclic compounds as fgfr inhibitors | |
| SI2917217T1 (sl) | Substituirani triciklični benzimidazoli kot inhibitorji kinaz | |
| IL239193A0 (en) | New Benzimidazole Derivatives as Kinase Inhibitors | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| SG11201501815UA (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| EP2900243A4 (en) | BICYCLIC OXA LACTAM KINASE HEMMER |